BNH Investment

Founded in 2014, Bertis is a South Korean company specializing in proteomics-based molecular diagnostics. It develops and commercializes cancer-related biomarkers for early detection of the disease, with its flagship product being Mastocheck, a screening method for stage 1 breast cancer.

Medinno is a South Korean biotechnology company based in Suwon that focuses on the research and development of neural stem cell–based therapies derived from adult brain tissue for degenerative neurological diseases. It develops cell therapeutics for brain disorders, with applications including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, severe intraventricular hemorrhages, stroke, and Alzheimer's disease.

PinotBio, founded in 2017, is a biotechnology company based in Suwon, South Korea. It specializes in the research and development of new small molecule drugs for ophthalmology and oncology fields.

IVIM Technology, founded in 2017 and based in Daejeon, South Korea, specializes in developing and manufacturing advanced medical devices, particularly the IntraVital Microscopy platform. The company provides services such as live cell intravital imaging, repetitive intravital imaging, drug efficacy monitoring, delivery monitoring, and whole tissue 3D imaging. IVIM Technology's innovations focus on exploring cellular interactions within living organisms to understand complex human diseases better. Their technology is instrumental in analyzing the in vivo efficacy of new biopharmaceuticals, including immunological, cell, gene, and antibody therapeutic agents, at the cellular level.

ImmuneOncia Therapeutics Inc. is a biopharmaceutical company focused on developing anti-cancer therapies, specifically in the field of immuno-oncology. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company is headquartered in Yongin-Si, South Korea. ImmuneOncia is dedicated to creating safe and effective immunotherapies for cancer patients worldwide, leveraging the expertise of its parent companies in drug development and antibody engineering. The company’s lead product, IMC-001, is a monoclonal antibody currently undergoing Phase 1 clinical trials, with a portfolio that includes various immune checkpoint antibodies aimed at treating multiple cancer types.

Founded in 2014, Bertis is a South Korean company specializing in proteomics-based molecular diagnostics. It develops and commercializes cancer-related biomarkers for early detection of the disease, with its flagship product being Mastocheck, a screening method for stage 1 breast cancer.

JLK, Inc. is a South Korean company specializing in artificial intelligence-driven medical and security solutions. It develops advanced AI platforms that support diagnosis and treatment by providing real-time, on-site services integrated with hospital systems. JLK focuses on a range of medical conditions, offering solutions for brain diseases such as ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer's disease, as well as lung diseases, coronary artery disease, and prostate cancer. The company also emphasizes digital pathology and data analysis in its offerings. Formerly known as JLK INSPECTION Co., Ltd., JLK, Inc. is headquartered in Cheongju, South Korea.